Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) announced that results from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome have ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE